Selective and potent small-molecule inhibitors of PI3Ks

Future Medicinal Chemistry

Volumn 6, Issue 7, 2014, Pages 737-756

  Jeong, Yujeong ^a,b   Kwon, Daeil ^a   Hong, Sungwoo ^a,b  

^a Institute for Basic Science   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 [5 (4 FLUORO 2 HYDROXYPHENYL)FURFURYLIDENE] 2,4 THIAZOLIDINEDIONE; ADENOSINE TRIPHOSPHATE; AMG 511; ANTINEOPLASTIC AGENT; BUPARLISIB; CNX 1351; DACTOLISIB; DW 12; E 5; E5E2; GNE 490; GNE 493; HSW 104; HSW 178; HSW 243; IDELALISIB; IMIDAZOPYRIDINE DERIVATIVE; MORPHOLINE DERIVATIVE; NVP BYL 719; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PTERIDINONE; STAUROSPORINE; UNCLASSIFIED DRUG; WORTMANNIN; ISOPROTEIN; MOLECULAR LIBRARY;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING SITE; CELL CYCLE ARREST; CELL DIVISION; CELL GROWTH; CELL METABOLISM; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; DNA REPAIR; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG INHIBITION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; GLIOBLASTOMA; HINGE REGION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DOCKING; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW; SEQUENCE ALIGNMENT; STEREOSPECIFICITY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PROCEDURES;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; SMALL MOLECULE LIBRARIES;

EID: 84903160594     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.28     Document Type: Review

References (61)

1. Wu P, Hu Y. Small molecules targeting phosphoinositide 3-kinases. Med. Chem. Commun. 3(11), 1337-1355 (2012
2. Leevers SJ, Vanhaesebroeck B, Waterfield MD. Signalling through phosphoinositide 3-kinases: The lipids take centre stage. Curr. Opin. Cell Biol. 11(2), 219-225 (1999
3. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7(8), 606-619 (2006
4. Vanhaesebroeck B, Leevers SJ, Ahmadi K et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70, 535-602 (2001
5. Engelman JA. Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat. Rev. Cancer 9(8), 550-562 (2009
6. Vivianco I, Sawyers CL. The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat. Rev. Cancer 2(7), 489-501 (2002
7. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670), 554 (2004). (Pubitemid 38541907
8. Massion PP, Kuo WL, Stokoe D et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: Implications of the phosphatidylinositol 3-kinase pathway. Cancer Res. 62(13), 3636-3640 (2002
9. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: The PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6(3), 184-192 (2006
10. Kim O, Jeong Y, Hong S-S, Hong S et al. Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis. J. Med. Chem. 54(7), 2455-2466 (2011
11. Jackson SP, Schoenwaelder SM, Goncalves I et al. PI 3-kinase p110ß: A new target for antithrombotic therapy. Nat. Med. 11(5), 507-514 (2005
12. Lin H, Erhard K, Hardwicke MA et al. Synthesis and structure-Activity relationships of imidazo[1,2-A]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors. Bioorg. Med. Chem. Lett. 22(6), 2230-2234 (2012
13. Pomel V, Klicic J, Covini D et al. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase. J. Med. Chem. 49(13), 3857-3871 (2006
14. Herman, SE, Gordon AL, Wagner AJ et al. Phosphatidylinositol 3-kinase-d inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116(12), 2078-2088 (2010
15. Lannuti BJ, Meadows SA, Herman SE et al. CAL-101, a p110d selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117(2), 591-594 (2011
16. Nacht M, Qiao L, Sheets MP et al. Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Ka. J. Med. Chem. 56(3), 712-721 (2013
17. Bowles DW, Jimeno A. New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin. Invest. Drugs 20(4), 507-518 (2011
18. Furet P, Guagnano V, Fairhurst RA et al. Discovery of NVPBYL719a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg. Med. Chem. Lett. 23(13), 3741-3748 (2013
19. Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: The role of phosphatidylinositol 3,4,5-Triphosphate in neutrophil responses. Biochem. J. 296(2), 297-301 (1993
20. Powis G, Bonjouklian R, Berggren MM et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res. 54(9), 2419-2423 (1994
21. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269(7), 5241-5248 (1994
22. Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the PI3 kinome: From chemical tools to drugs in the clinic. Cancer Res. 70(6), 2146-2157 (2010
23. Palanki MS, Dneprovskaia E, Doukas J et al. Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozymeselective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction. J. Med. Chem. 50(18), 4279-4294 (2007
24. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9(1), 28-39 (2009
25. Cherry M, Williams DH. Recent kinase and kinase inhibitor x-ray structures: Mechanisms of inhibition and selectivity insights. Curr. Med. Chem. 11(6), 663-673 (2004
26. Johnson LN, Lowe ED, Noble ME, Owen DJ. The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases. FEBS Lett. 430(1), 1-11 (1998
27. Manning G, Whyte DB, Martinez R et al. The protein kinase complement of the human genome. Science 298(5600), 1912-1934 (2002
28. Traxler P, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. 82(2-3), 195-206 (1999
29. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2(7), 358-364 (2006
30. Walker EH, Pacold ME, Perisic O, Stephens L et al. Structural Determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell. 6(4), 909-919 (2000
31. Sundstrom TJ, Anderson AC, Wright DL. Inhibitors of phosphoinositide-3- kinase: A structure-based approach to understanding potency and selectivity. Org. Biomol. Chem. 7(5), 840-850 (2009
32. Xie P, Williams DS, Atilla-Gokcumen GE et al. Structurebased design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. ACS Chem. Biol. 3(5), 305-316 (2008
33. Liu KK, Bagrodia S, Bailey S et al. 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors. Bioorg. Med. Chem. Lett. 20(20), 6096-6099 (2010
34. Peterson EA, Andrews PS, Be X et al. Discovery of triazinebenzimidazoles as selective inhibitors of mTOR. Bioorg. Med. Chem. Lett. 21(7), 2064-2070 (2011
35. Jeong Y, Lee J, Hong S et al. Selectivity enhancement arising from interactions at the PI3K unique pocket. ChemMedChem 7(8), 1379-1383 (2012
36. Atilla-Gokcumen GE, Williams DS, Bregman H et al. Organometallic compounds with biological activity: A very selective and highly potent cellular inhibitor for glycogen synthase kinase 3. ChemBioChem 7(9), 1443-1450 (2006
37. Bregman H, Meggers E. Ruthenium half-sandwich complexes as protein kinase inhibitors: An N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety. Org. Lett. 8(24), 5465-5468 (2006
38. Norman MH, Andrews KL, Bo YY et al. Selective class I phosphoinositide 3-kinase inhibitors: Optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511. J. Med. Chem. 55(17), 7796-7816 (2012
39. Smith AL. D'Angelo N, Bo YY et al. Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases. J. Med. Chem. 55(11), 5188-5219 (2012
40. Fabian MA, Biggs WH, Treiber DK et al. A small moleculekinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23(3), 329-336 (2005
41. Sutherlin DP, Sampath D, Berry M et al. Discovery of (thienopyrimidin-2- yl)aminopyrimidines as potent, selective, and orally available pan-pi3-kinase and dual pan-pi3-kinase/mtor inhibitors for the treatment of cancer. J. Med. Chem. 53(3), 1086-1097 (2010
42. Folkes AJ, Ahmadi K, Alderton WK et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-Thieno-[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51(18), 5522-5532 (2008
43. Hayakawa M, Kaizawa H, Moritomo H et al. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase PI3KR inhibitors. Bioorg. Med. Chem. 14(20), 6847-6858 (2006
44. Stein RC, Waterfield MD. PI3-kinase inhibition: A target for drug development?. Mol. Med. Today 6(9), 347-357 (2000
45. Heffron TP, Wei B, Olivero A et al. Rational design of phosphoinositide 3-kinase a inhibitors that exhibit selectivity over the phosphoinositide 3-kinase ß isoform. J. Med. Chem. 54(22), 7815-7833 (2011
46. Huang CH, Mandelker D, Schmidt-Kittler O et al. The structure of a human p110a/p85a complex elucidates the effects of oncogenic PI3Ka mutations. Science 318(5857), 1744-1748 (2007
47. Lin H, Schulz MJ, Xie R et al. Rational design, synthesis, and SAR of a novel thiazolopyrimidinone series of selective PI3Kbeta inhibitors. ACS Med. Chem. Lett. 3(7), 524-529 (2012
48. Sanchez RM, Erhard K, Hardwicke MA et al. Synthesis and structure-Activity relationships of 1,2,4-Triazolo[1,5-A] pyrimidin-7(3H)-ones as novel series of potent b isoform selective phosphatidylinositol 3-kinase inhibitors. Bioorg. Med. Chem. Lett. 22(9), 3198-3202 (2012
49. Kim J, Hong S, Hong S. Discovery of new aminopyrimidinebased phosphoinositide 3-kinase beta (PI3Kß) inhibitors with selectivity over PI3Ka. Bioorg. Med. Chem. Lett. 21(23), 6977-6981 (2011
50. Stec MM, Andrews KL, Booker SK et al. Structure-Activity relationships of phosphoinositide 3-kinase (PI3K)/ mammalian target of rapamycin (mTOR) dual inhibitors: Investigations of various 6,5-heterocycles to improve metabolic stability. J. Med. Chem. 54(14), 5174-5184 (2011
51. D'Angelo ND, Kim TS, Andrews K et al. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors. J. Med. Chem. 54(6), 1789-1811 (2011
52. Sutherlin DP, Bao L, Berry M et al. Discovery of a potent, selective, and orally available class i phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J. Med. Chem. 54(21), 7579-7578 (2011
53. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351(1), 95-105 (2000
54. Klarenbeek S, van Miltenburg MH, Jonkers J. Genetically engineered mouse models of PI3K signaling in breast cancer. Mol. Oncol. 7(2), 146-164 (2013
55. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin. Ther. Targets 16(1), 121-130 (2012
56. Burger MT, Pecchi S, Maira S-M, Voliva CF. Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer. ACS Med. Chem. Lett. 2(10), 774-779 (2011
57. Knight ZA, Chiang GG, Alaimo PJ et al. Isoform specific phosphoinositide-3-kinase inhibitors from an arylmorpholine scaffold. Bioorg. Med. Chem. 12(17), 4749-4759(2004
58. Maira SM, Pecchi S, Huang A et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol. Cancer Ther. 11(2), 317-328 (2012
59. Bruce I, Akhlaq M, Bloomfield GC et al. Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway. Bioorg. Med. Chem. Lett. 22(17), 5445-5450 (2012
60. Fritsch CM, Schnell C, Chatenay-Rivauday C et al. NVPBYL719, a novel PI3Kalpha selective inhibitor with all the characteristics required for clinical development as an anticancer agent. Cancer Res. 72(Suppl. 8), Abstract 3748 (2012
61. Castillo JJ, Furman M, Winer ES. CAL-101: A phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin. Invest. Drugs 21(1), 15-22 (2012.